World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
42564
World Ranking
11562
National Ranking
5933

Mark A. Socinski publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark A. Socinski sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 766 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark A. Socinski D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark A. Socinski sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark A. Socinski is affiliated with the University of North Carolina at Chapel Hill in the United States. The primary field of study is Medicine, with a significant focus on Oncology and Pulmonary and Respiratory Medicine. Their research also spans Cancer Research, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist's work centers on several key topics, including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • HER2/EGFR in Cancer Research
  • Cancer Genomics and Diagnostics

Mark A. Socinski has been published extensively across multiple venues. Frequent publication platforms include:

  • UNC Libraries
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Clinical Lung Cancer

Their recent papers reflect ongoing contributions to clinical oncology and lung cancer research. Notable publications include:

  • "Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial," 2020, Journal of Thoracic Oncology
  • "IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC," 2021, Journal of Thoracic Oncology
  • "Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial," 2020, Journal of Thoracic Oncology
  • "IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain," 2021, Journal of Thoracic Oncology
  • "Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer," 2023, JAMA Oncology

Collaboration is a part of Mark A. Socinski's research approach, working with frequent co-authors including:

  • Thomas E. Stinchcombe
  • Makoto Nishio
  • Robert M. Jotte
  • Federico Cappuzzo
  • Martin Reck

Best Publications

  • Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

    Mark A. Socinski;Robert M. Jotte;Federico Cappuzzo;Francisco Orlandi

  • First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

    David P. Carbone;Martin Reck;Luis Paz-Ares;Benjamin Creelan

  • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

    Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski

  • Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

    Mark G. Kris;Bruce E. Johnson;Lynne D. Berry;David J. Kwiatkowski

  • Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

    Martin Reck;Tony S K Mok;Makoto Nishio;Robert M Jotte

  • Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

    Mark A. Socinski;Igor Bondarenko;Nina A. Karaseva;Anatoly M. Makhson

  • Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced Myelosuppression

    Karen S. Antman;James D. Griffin;Anthony Elias;Mark A. Socinski

  • GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN

    MarkA. Socinski;Anthony Elias;Lowell Schnipper;StephenA. Cannistra

  • Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

    Alice T Shaw;Leena Gandhi;Shirish Gadgeel;Gregory J Riely

  • Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial

    Jean Yves Douillard;Frances A. Shepherd;Vera Hirsh;Tony Mok

  • Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

    Charles Butts;Mark A Socinski;Paul L R Mitchell;Nick Thatcher

  • Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

    Mark A. Socinski;Michael J. Schell;Amy Peterman;Kamal Bakri

  • Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer

    Daniel B. Fried;David E. Morris;Charles Poole;Julian G. Rosenman

  • Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial

    David Planchard;Tae Min Kim;Julien Mazieres;Elisabeth Quoix

  • Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

    Robert Jotte;Federico Cappuzzo;Ihor Vynnychenko;Daniil Stroyakovskiy

  • PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

    Jyoti D. Patel;Mark A. Socinski;Edward B. Garon;Craig H. Reynolds

  • Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer

    Mark A. Socinski;Silvia Novello;Julie R. Brahmer;Rafael Rosell

  • Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

    Kyle Wang;Michael J. Eblan;Allison M. Deal;Matthew Lipner

  • Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.

    Nick Thatcher;Fred R Hirsch;Alexander V Luft;Aleksandra Szczesna

  • Gene Expression Profiling Reveals Reproducible Human Lung Adenocarcinoma Subtypes in Multiple Independent Patient Cohorts

    D. Neil Hayes;Stefano Monti;Giovanni Parmigiani;C. Blake Gilks

Frequent Co-Authors

Martin Reck
Martin Reck LungenClinic Grosshansdorf
Ramaswamy Govindan
Ramaswamy Govindan Washington University in St. Louis
David R. Spigel
David R. Spigel Sarah Cannon Research Institute
Corey J. Langer
Corey J. Langer University of Pennsylvania
Nick Thatcher
Nick Thatcher University of Manchester
Silvia Novello
Silvia Novello University of Turin
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Frank C. Detterbeck
Frank C. Detterbeck Yale University
Everett E. Vokes
Everett E. Vokes University of Chicago
Tony Mok
Tony Mok Chinese University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a variety of online degree options and career paths in healthcare. Many students look for flexible, accredited programs to balance education with work or family commitments. Entry points include options like lpn online programs, which offer a fast track to licensure and a career in nursing.

Advanced nursing degrees, such as the DNP (Doctor of Nursing Practice), are also available fully online. Students searching for convenience and efficiency can explore dnp online programs and find options tailored to different schedules and career goals. For those aiming to expedite their studies further, some institutions feature the shortest dnp program with condensed coursework and quicker timelines to graduation.

Mental health is a growing specialty, and the shortest pmhnp program provides a streamlined route to becoming a Psychiatric Mental Health Nurse Practitioner. Each pathway offers different benefits, letting you align your education with your career aspirations in medicine and healthcare.

Best Scientists Citing Mark A. Socinski

Trending Scientists

Recently Published Articles